These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 12392732)

  • 1. Discovery and biological characterization of capromorelin analogues with extended half-lives.
    Carpino PA; Lefker BA; Toler SM; Pan LC; Hadcock JR; Murray MC; Cook ER; DiBrino JN; DeNinno SL; Chidsey-Frink KL; Hada WA; Inthavongsay J; Lewis SK; Mangano FM; Mullins MA; Nickerson DF; Ng O; Pirie CM; Ragan JA; Rose CR; Tess DA; Wright AS; Yu L; Zawistoski MP; Pettersen JC; DaSilva-Jardine PA; Wilson TC; Thompson DD
    Bioorg Med Chem Lett; 2002 Nov; 12(22):3279-82. PubMed ID: 12392732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyrazolinone-piperidine dipeptide growth hormone secretagogues (GHSs). Discovery of capromorelin.
    Carpino PA; Lefker BA; Toler SM; Pan LC; Hadcock JR; Cook ER; DiBrino JN; Campeta AM; DeNinno SL; Chidsey-Frink KL; Hada WA; Inthavongsay J; Mangano FM; Mullins MA; Nickerson DF; Ng O; Pirie CM; Ragan JA; Rose CR; Tess DA; Wright AS; Yu L; Zawistoski MP; DaSilva-Jardine PA; Wilson TC; Thompson DD
    Bioorg Med Chem; 2003 Feb; 11(4):581-90. PubMed ID: 12538023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capromorelin increases food consumption, body weight, growth hormone, and sustained insulin-like growth factor 1 concentrations when administered to healthy adult Beagle dogs.
    Zollers B; Rhodes L; Smith RG
    J Vet Pharmacol Ther; 2017 Apr; 40(2):140-147. PubMed ID: 27597271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the safety in dogs of long-term, daily oral administration of capromorelin, a novel drug for stimulation of appetite.
    Zollers B; Huebner M; Armintrout G; Rausch-Derra LC; Rhodes L
    J Vet Pharmacol Ther; 2017 Jun; 40(3):248-255. PubMed ID: 27665742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the safety of daily administration of capromorelin in cats.
    Wofford JA; Zollers B; Rhodes L; Bell M; Heinen E
    J Vet Pharmacol Ther; 2018 Apr; 41(2):324-333. PubMed ID: 29057482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological profile of a new orally active growth hormone secretagogue, SM-130686.
    Nagamine J; Nagata R; Seki H; Nomura-Akimaru N; Ueki Y; Kumagai K; Taiji M; Noguchi H
    J Endocrinol; 2001 Dec; 171(3):481-9. PubMed ID: 11739014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children.
    Codner E; Cassorla F; Tiulpakov AN; Mericq MV; Avila A; Pescovitz OH; Svensson J; Cerchio K; Krupa D; Gertz BJ; Murphy G
    Clin Pharmacol Ther; 2001 Jul; 70(1):91-8. PubMed ID: 11452249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testosterone inhibition of growth hormone release stimulated by a growth hormone secretagogue: studies in the rat and dog.
    Rigamonti AE; Cella SG; Giordani C; Bonomo SM; Giunta M; Sartorio A; Muller E
    Neuroendocrinology; 2006; 84(2):115-22. PubMed ID: 17106185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of an oral growth hormone secretagogue in older adults.
    White HK; Petrie CD; Landschulz W; MacLean D; Taylor A; Lyles K; Wei JY; Hoffman AR; Salvatori R; Ettinger MP; Morey MC; Blackman MR; Merriam GR;
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1198-206. PubMed ID: 19174493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residues.
    Qiao JX; Cheng X; Smallheer JM; Galemmo RA; Drummond S; Pinto DJ; Cheney DL; He K; Wong PC; Luettgen JM; Knabb RM; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1432-7. PubMed ID: 17174550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substituted bridged phenyl piperidines: orally active growth hormone secretagogues.
    Lu Z; Tata JR; Cheng K; Wei L; Chan WW; Butler B; Schleim KD; Jacks TM; Hickey G; Patchett AA
    Bioorg Med Chem Lett; 2003 May; 13(10):1817-20. PubMed ID: 12729672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capromorelin oral solution (ENTYCE®) increases food consumption and body weight when administered for 4 consecutive days to healthy adult Beagle dogs in a randomized, masked, placebo controlled study.
    Zollers B; Rhodes L; Heinen E
    BMC Vet Res; 2017 Jan; 13(1):10. PubMed ID: 28056951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Prospective, Randomized, Masked, Placebo-Controlled Clinical Study of Capromorelin in Dogs with Reduced Appetite.
    Zollers B; Wofford JA; Heinen E; Huebner M; Rhodes L
    J Vet Intern Med; 2016 Nov; 30(6):1851-1857. PubMed ID: 27859746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeat administration of the GH secretagogue MK-0677 increases and maintains elevated IGF-I levels in beagles.
    Hickey GJ; Jacks TM; Schleim KD; Frazier E; Chen HY; Krupa D; Feeney W; Nargund RP; Patchett AA; Smith RG
    J Endocrinol; 1997 Feb; 152(2):183-92. PubMed ID: 9071975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth hormone and growth hormone-related mRNA in uremic rats: effect of a growth hormone secretagogue.
    Krieg RJ; Chan W; Lin KC; Kuemmerle NB; Veldhuis JD; Chan JC
    Pediatr Nephrol; 2002 Aug; 17(8):585-90. PubMed ID: 12185462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-like growth factor-1 and growth hormone (GH) levels in canine cerebrospinal fluid are unaffected by GH or GH secretagogue (MK-0677) administration.
    Prahalada S; Block G; Handt L; DeBurlet G; Cahill M; Hoe CM; van Zwieten MJ
    Horm Metab Res; 1999; 31(2-3):133-7. PubMed ID: 10226793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increases in circulating insulin-like growth factor I levels by the oral growth hormone secretagogue MK-0677 in the beagle are dependent upon pituitary mediation.
    Schleim KD; Jacks T; Cunningham P; Feeney W; Frazier EG; Niebauer GW; Zhang D; Chen H; Smith RG; Hickey G
    Endocrinology; 1999 Apr; 140(4):1552-8. PubMed ID: 10098487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1-[2(R)-(2-amino-2-methylpropionylamino)-3-(1H-indol-3-yl)propionyl]- 3-benzylpiperidine-3(S)-carboxylic acid ethyl ester (L-163,540): a potent, orally bioavailable, and short-duration growth hormone secretagogue.
    Yang L; Morriello G; Patchett AA; Leung K; Jacks T; Cheng K; Schleim KD; Feeney W; Chan WW; Chiu SH; Smith RG
    J Med Chem; 1998 Jul; 41(14):2439-41. PubMed ID: 9651148
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluating the Safety and Efficacy of Capromorelin in Rhesus Macaques (
    Campellone GA; Easley KA; Jenkins JB; Jean SM
    J Am Assoc Lab Anim Sci; 2024 May; 63(3):268-278. PubMed ID: 38423529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of the ghrelin agonist capromorelin in a single ascending dose Phase-I safety trial in spinal cord-injured and able-bodied volunteers.
    Ellis AG; Zeglinski PT; Brown DJ; Frauman AG; Millard M; Furness JB
    Spinal Cord; 2015 Feb; 53(2):103-8. PubMed ID: 25448190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.